CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA) today announced it will investigate the ability of its...
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer...
First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade...
Health journaling app leverages the latest technology in natural language processing (NLP) to provide insightful summaries that could impact care...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2...
HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell...
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and...
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026,...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor...
SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to...
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing...
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
Interim Analysis Anticipated at end of Q1 2025 SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage...
MINNETONKA, Minn., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Canon Medical Informatics, Inc. today announced that a leading non-profit health system...
6-month efficacy and safety data from ongoing Phase 1/2 trial of OPGx-LCA5 to be presentedFARMINGTON HILLS, Mich., Dec. 03, 2024...
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
PARAMUS, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming...
Strategic appointments support further growth and position Company for future success WESTLAKE VILLAGE, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) --...
Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit...